Glioblastoma multiforme (GBM) is a chemotherapy-resistant brain tumor with limited
treatment options. Temozolomide (TMZ), an alkylating agent, is a front-line …

Glioma is the most common malignant tumor of the central nervous system with poor
survival. Temozolomide (TMZ) is the first-line chemotherapy drug for initial and recurrent …

Temozolomide (TMZ) is a promising chemotherapeutic agent to treat Glioblastoma
multiforme (GBM). However, resistance to TMZ develops quickly with a high frequency. The …

Temozolomide (TMZ) with radiotherapy is the current standard of care for newly diagnosed
glioma. However, glioma patients who are treated with the drug often develop resistance to it …

Background: Glioblastoma multiforme (GBM) is a form of highly malignant brain tumour.
Temozolomide (TMZ) is the standard agent for GBM, but TMZ-resistance is common and …

Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system,
and chemoresistance blunts the effect of temozolomide (TMZ) in the treatment of GBM …

Temozolomide is a first line anti-tumor drug used for the treatment of patients with
Glioblastoma multiforme (GBM). However, the drug resistance to temozolomide limits its …

The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a major
burden for patients suffering from glioma. Recently, studies have demonstrated that micro …

Increasing evidence indicates that microRNAs (miRNAs) participate in the regulation of
chemoresistance in a variety of cancers including glioma. However, the molecular …

Glioblastoma is one of the most frequent and aggressive brain tumors. Accumulating
evidence indicates that microRNAs are involved in glioma proliferation, invasion and drug …